名古屋大学 · 医学
Kohei Shitata教授の研究室では、胃がんや食道がんを対象としたがん免疫療法の最前線の研究が進められています。特にPD-1阻害剤を用いた治療戦略や、HER2陽性・陰性胃がんに対する標的療法の効果的応用に注力しており、臨床的有用性の高い治療法の確立を目指しています。また、免疫チェックポイント阻害剤に対する耐性メカニズムの解明や、予後予測因子の同定も重要な研究テーマです。
Figures are computed from collected data and may differ slightly.
Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number, NCT03329690.).
ClinicalTrials.gov Identifier: NCT02494583.
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma<sup>1-4</sup>. Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized, global CheckMate 649 phase 3 trial<sup>5</sup> (programmed death ligand-1 (PD-L1) co
Cancer immunotherapy involving blockade of immune checkpoint molecules, such as CTLA-4 and PD-1, has shown remarkable clinical success across several types of malignancies. However, a fraction of patients experience disease progression after treatment; thus, exploring resistant mechanisms for immune checkpoint inhibitors and improving their treatment outcome with additional modalities are of great importance. CD4<sup>+</sup> regulatory T (T<sub>reg</sub> ) cells characterized by expression of th
Some features were associated with favorable response to nivolumab for AGC. Combining these features might be useful to predict efficacy.
Open papers in the app to read, cite, and organize with AI.
